Member Info for closettrader

So off the top of my head over the last 3 months we have had:
- Testing for SNG-001 starts in hospital at end of March results due in 8 weeks
- testing extended to at home testing results due July
- In April WHO includes interferon in conjunction with Remdesivir as one of only 5 treatments being tested
- Marsden quoted as saying “ this could be our time”
- AZN renews relationship with Soton hospital
- Daily Mail and Sun talk of a vaccine delivered via an inhaler being developed by AZN
- continued search for volunteers in the Soton area
- Marsden quoted a saying SNG-001 could prevent a bad second week after being infected by Covid-19
- Eleanor Fish, Professor of Immunology at University of Toronto. has been advocating strongly the use of Interferon in the treatment of Covid-19 and other respiratory diseases
- Newcastle GP on Friday when talking about the dangers of COPD being a danger to patients being infected with Covid-19

I have no doubt missed many other positive references to anecdotal evidence of interferon being key in boosting the bodies defence against Covid-19........ and then we have a classic 55% retrace from recent highs coinciding with Link Fund holding being bought by Acacia coincidentally at the placing price of 35p...... and then on Friday a very brief dip below 35p and a surge up in the afternoon with many NT periods.

Do I think this week will be a positive one......yep!

So off the top of my head over the last few months we have:
- Marsden “This could be our time“
- Testing started end of Mar

“In response to any and all viruses, the very first we do is make interferons. That, if nothing else, should tell you they are important. In addition, viruses have evolved to very specifically block interferon production. So coming in with interferon has the potential to override or swing the balance in favor of the host,” she explained.

Dr. Fish noted that the biggest fear with interferon is the potential to generate a “cytokine storm,” but there is “absolutely no evidence of that” from the SARS outbreak in Toronto or in COVID-19 patients. “If anything, the evidence was in the other direction, that we reduce the inflammatory response. Fear of cytokine storm I really think needs to be put to bed once and for all,” Dr. Fish said.

Why inhaled interferon in this study? “We went with what we could mobilize quickly and in Wuhan that was nebulized interferon,” Dr. Fish said. It’s unclear now which route of administration is going to be most efficient. “We are doing trials now to answer that.”

Dr. Fish also sees a potential prophylactic role for interferon for healthcare workers, others severely at risk, the elderly, the immunocompromised, and post-exposure individuals.

This has probably been posted before, so apologies for those that have read it already:
BIOTECHNOLOGYMAY 20, 2020 / 3:41 PM / 25 DAYS AGO
Interferon therapy may speed recovery from COVID-19
Megan Brooks
4 MIN READ
NEW YORK (Reuters Health) - Treatment with the antiviral interferon alfa-2b (IFN-a2b) appears to speed up virus clearance and lower levels of key inflammatory markers in patients with COVID-19, according to an exploratory study conducted in Wuhan, China.
This study provides “the first compelling evidence of a potential treatment that is approved and we have decades of experience with,” Dr. Eleanor Fish of the Toronto General Hospital Research Institute and the University of Toronto Department of Immunology, in Canada, told Reuters Health by phone.
In a paper in Frontiers of Immunology, Dr. Fish and colleagues report the clinical course of 77 adults with confirmed COVID-19 who were treated with inhaled IFN-a2b (5 mU b.i.d), arbidol (200 mg t.i.d) or the combination of both broad-spectrum antivirals. All patients had only moderate illness; none required intensive care or oxygen supplementation or intubation.
Compared with arbidol alone (27.9 days), IFN-a2b treatment, with (20.3 days) or without arbidol (21.1 days), was associated with significantly accelerated viral clearance from the respiratory tract and reduced duration of elevated blood levels of the inflammatory markers interleukin-6 and C-reactive protein, the researchers report.
With IFN-a2b, “we achieved accelerated viral clearance by about seven days, which is faster than with remdesivir, and we showed a reduction in circulating levels of inflammatory markers, which really exacerbate disease,” Dr. Fish told Reuters Health.
Age, co-morbidities and sex did not negate the effects of IFN treatment on viral clearance times or on the reduction in the inflammatory markers.
“This was an exploratory study, but I see absolutely no reason why these exploratory studies should not have relevancy. Very often they are dismissed because they are not the gold-standard randomized controlled trial, which are very difficult to do during an outbreak,” Dr. Fish commented.
She and her colleagues previously demonstrated the therapeutic benefit of interferon during the Toronto SARS outbreak of 2002 and 2003. In that study, IFN treatment seemed to speed up the resolution of lung abnormalities in SARS-infected patients.
“Interferons are broad-spectrum antivirals that should be considered as ‘first responders’ for all acute virus infections that are severe,” Dr. Fish said. “The beauty is you don’t have to know the virus. Because they are polytrophic, they target many different facets and stages of a virus’ lifecycle and in addition they muster and activate immune cells to help clear the virus.”

Just seen a GP from Newcastle On BBC News at 10 saying that people suffering from pre-existing chronic diseases such as COPD will be at greater risk if they contract with Covid virus...... I know all on this board probably know this but bringing the disease more to the attention of the public ...... do we know a possible way of reducing the risk......?

Not really big news!!!! Are you bonkers! Our Company has specifically been mentioned by the transport minister in this evenings CV update ....... absolutely huge recognition and brilliant PR

Actual spread now 40.05/40.7........the 40's are back....yes!!

No can buy.....looking like a strong finish

Can't buy....can sell at 38p. Classic chart retrace from 72p high that also matches placement price. Could get interesting this pm and next week..........

The Company seems to have made net investments of about $70 million, most of which seems to have been subsequently written off and had expenditures of about $57 million. Of that $57 million, about $16 million went to pay employees and, beginning in 2015, OAL after the Company in 2014 adopted a fund rather than operating company structure. About $11.5 million went to pay "professionals," presumably primarily lawyers. About $4.6 million went to pay directors. About $3.6 million was paid in fees in connection with the 2011 capital raise. The auditors received about $1.6 million. The remaining $19 million is hard to put your finger on because it is buried within accounting categories that are not self-explanatory.

The Origo story is a dismal one with lots of blame to go around beginning with the Board, who are ultimately responsible for what happens inside a public company, the manager/advisor for obvious reasons, the previous Nomad and the previous auditors. In light of the facts set forth above, we will solicit the views of our shareholders on how they wish to proceed and provide further details in due course.

Very truly yours,

John D. Chapman

Chairman

I've seen some dodgy companies but how about this....from results to Dec 2018....
Origo's Catastrophic Destruction of Shareholder Value

Origo represents a catastrophic destruction of shareholder value. Of the approximately $276 million that the Company raised, only about $6.3 million remains on the Company balance sheet mostly in the form of cash and a few investments noted above. No real capital was ever returned to shareholders. The Company never paid a dividend and besides peculiar share repurchases in 2012 and a few years later totalling a little more than $700,000, never returned capital through a buy back. The remainder was dissipated in, as best as we can tell, shockingly bad investments, fees paid to OAL and others, fees paid to former board members, fees paid to the former Nomad, fees paid to lawyers, fees paid to previous auditors and so on.

Several of us trying to unravel the Origo story have noticed that so much of what the Company did benefited a privileged few to the detriment of the Company's shareholders. So, a former director's daughter ended up with a board seat and also a consulting contract. The father of an OAL principal ended up in some business relationship with the Company. An early investor in the Company, a large London based "hedge fund," paid the Company for "research." The Company then rebated much of this payment to an employee of the hedge fund who also happened to be the then Executive Chairman's wife. Non-transparent subsidiary companies were formed where insiders and family members seem to have had financial interests. Origo made investments in a company, and later its former CEO went to work for an affiliate of that company. Lawyers, even by London standards, did shockingly well. The previous Nomad, the lawyers and the former auditors were well paid for work that had little or no benefit to shareholders. OAL was rewarded with interest accruing at 8% in order to pay the fees that the Company was unable to pay because OAL had failed to sell assets sufficient to pay its fees. And so on.

There are many ways to slice and dice the Origo numbers, and, unfortunately, we do not now control all of the information necessary to forensically dissect the Company. The former board has not been forthcoming in providing information and a lot of the Company records we have received are a mess. Our administrator's accountants have thus used Origo's published accounts and by working backward have tried to recreate the Company's flow of funds. There are, unfortunately, still some large gaps in our knowledge.

Nonetheless, we think it is possible to roughly show where the money went. On 1 January 2011, Origo had cash in the bank of $33.4 million. During 2011 the Company raised $92.5 million. In 2016, the Company also borrowed $2.5 million in order to meet its expenses since by that time it had burned though most of its cash. So roughly where did that money go?

The Company seems to have made net inve

Say a Care Home has one resident infected with Covid-19........ SNG is then given to the other residents to help boost their interferon levels to help them from being infected. Would SNG then be thought of as a treatment (but the patients aren’t infected) or a ‘vaccine’ to help prevent infection? So is this reference to a ‘vaccine’ the same as featured in the articles in last weekend’s Sun and D. Mail? ..... with the link to Southampton, AZN, an inhaler, trial start times and age of patients it all looks like a lot of circumstantial evidence coming together...... hopefully!

This is actually the link to the Martin French interview from 2019.....apologies....but definitely worth watching for any newbies
https://www.youtube.com/watch?v=ryAsZ3to3Hg

Just thought I'd copy my post from April 2020 here...apologies if you've seen it before.
This is a link to an interview by Exec. Chairman Martin French last year:
https://www.proactiveinvestors.co.uk/companies/stocktube/13385/mining-sector-urged-to-become-less-risk-averse-13385.html
....and this was my post in June 2019: 'Excellent interview....Chesterfield has an incredibly experienced Board for such a small Company. Looking for further copper prospects in Cyprus which historiically supported significant copper mining projects but which ceased 40 years ago after Turkish invasion. Martin French, Executive Chairman, has put £200,000 of his own money in and is very conscious of share dilution. £1.5m in the bank which will be enough for any immediate exploration costs and which will produce significant news flow over the next few months. Possible interest from partner (possibly Far Eastern) and possibility of near term cash flow (possibly from tailings from previous mining - that's my thought). Very low market cap and very few shares in circulation. Very interesting.........'

And now it seems we have Gold as well! There may well be another capital raise but I'm happy to NED Peter Damouni on our side.......from website 'Mr. Damouni has over 18 years of experience in investment banking and capital markets, with expertise in mining and oil and gas. Throughout his career, Mr. Damouni has worked on and led equity and debt financings valued over $5 billion. He has comprehensive experience in equity financing, restructuring, corporate valuations and advisory assignments.'

Well that's the placing price hit.......upwards from here now in anticipation of results......

Ss requested, From today's Daily Mail:
'Vaccine via Inhaler could be ready for August. The world may have a successful coronavirus vaccine as soon as next month.
An answer on whether the vaccine being developed at Oxford University works could come before the target date of August.
The team are now '80 per cent confident' it will work in younger people and say the vaccine could be given using a device like an asthma inhaler.
The news from Oxford, which aims to have 'tens of millions of doses' available for the UK by September after joining forces with AstraZeneca, came in an online lecture for Oxford University's Centre for Personalised Medicine by team member Professor Adrian Hill.
Clinical trials will end when the vaccine has clearly been found to protect people, Professor Hill said. 'We are guessing that might be around about August time - it might be before if cases do not decline as quickly as we expect, or be later if we run out of cases'.
The Oxford trial started in April and began recruiting adults over 55 and children for a trial of up to 10,260 people last month.
The big question is whether a vaccine will just prevent people dying and becoming severely unwell. Or, ideally, whether it will also stop virus transmission.
In the webinar, posted online on May 21, Professor Hill said: 'You would like a vaccine that does both. It's often harder to make a vaccine that prevents transmission than disease.'

Thought the news that Astrazeneca have a possible 'vaccine' using an inhaler that has been trialled since April woud have created a little debate....but there you go........

......and the inhaler?!.........

Or, should I say, it seems from this article the SNG-just may be the vaccine. ........ discuss

Synairgen is the vaccine.......